Biliary atresia is a condition in infants in which the bile ducts—tubes inside and outside the liver—are scarred and blocked. Bile ducts carry bile from the liver to the gallbladder for storage, and to the first part of the small intestine, also called the duodenum, for use in digestion. In infants with biliary atresia, bile can’t flow into the intestine, so bile builds up in the liver and damages it. The damage leads to scarring, loss of liver tissue and function, and cirrhosis.
The causes of biliary atresia are not completely understood. For some children, biliary atresia may occur because the bile ducts did not form properly during pregnancy. For other children with biliary atresia, the bile ducts may be damaged by the body's immune system in response to a viral infection acquired after birth.
Complications of biliary atresia include failure to thrive and malnutrition, cirrhosis and related complications, and liver failure. Without treatment, infants with biliary atresia would develop cirrhosis within 6 months and liver failure within 1 year. By age 2, untreated infants would need a liver transplant to survive. Biliary atresia is life-threatening, but with treatment, most infants with biliary atresia survive to adulthood.
Get FREE sample copy at:
The Biliary Atresia market report also covers emerging drugs, current treatment practices, Biliary Atresia market share of the individual therapies, current and forecasted Biliary Atresia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Biliary Atresia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Biliary Atresia Market Key Facts
According to the National Organization for Rare Disorders, Biliary atresia occurs in approximately 1 in 10,000 to 15,000 births in the United States.
Approximately 400-600 new cases of biliary atresia are encountered in the United States each year.
According to one estimate, the prevalence of biliary atresia in Europe is approximately 1 in 12,000 births.
As per the “American Liver Foundation”, up to 10-20% of infants with biliary atresia may have other associated malformations including multiple spleens, abnormal vessels supplying or draining the liver, or heart defects.
Key Benefits of Biliary Atresia Market Report
Biliary Atresia market report provides an in-depth analysis of Biliary Atresia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Biliary Atresia market report will help in developing business strategies by understanding the Biliary Atresia Market trends & developments, key players and future market competition that will shape and drive the Biliary Atresia market in the upcoming years.
The Biliary Atresia market report covers Biliary Atresia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Biliary Atresia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Biliary atresia cannot be prevented as there still is no clear cause of the disease. Some complications of biliary atresia can be treated temporarily with medications and special diets; liquid vitamin supplements can be given orally to help lessen deficiencies. The preferred biliary atresia treatment is the Kasai procedure. Without surgery, biliary atresia can be fatal.
There remains a large unmet need as currently there is no approved therapy for treating Biliary atresia. However, identifying the exact cause of biliary atresia can lead to earlier diagnostic screening tests and new treatment strategies. To redress the current issues, only a few companies are currently working toward this indication to meet the needs of the market.
The Biliary Atresia market size is anticipated to Increase during the study period, 2017–2030. The key driver for the surge in market size is the rise in number of incident cases of Biliary Atresia patients in 7MM.
The Biliary Atresia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Biliary Atresia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Biliary Atresia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Biliary Atresia Epidemiology
The Biliary Atresia epidemiology section covers insights about historical and current Biliary Atresia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Biliary Atresia Drugs Uptake and Key Market Players
The Biliary Atresia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched in the market during the study period. The analysis covers Biliary Atresia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Biliary Atresia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecast period.
The key players involved in developing therapies for Biliary Atresia includes Sirnaomics, Albireo and others.
Drugs Covered in Report
And few other.
Table of Content
1. Key Insights
2. Executive Summary
3. Biliary Atresia Competitive Intelligence Analysis
4. Biliary Atresia Market Overview at a Glance
5. Biliary Atresia Disease Background and Overview
6. Biliary Atresia Patient Journey
7. Biliary Atresia Epidemiology and Patient Population
8. Biliary Atresia Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Atresia Unmet Needs
10. Key Endpoints of Biliary Atresia Treatment
11. Biliary Atresia Marketed Products
12. Biliary Atresia Emerging Therapies
13. Biliary Atresia Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Atresia Market Outlook (7 major markets)
16. Biliary Atresia Access and Reimbursement Overview
17. KOL Views on the Biliary Atresia Market.
18. Biliary Atresia Market Drivers
19. Biliary Atresia Market Barriers
21. DelveInsight Capabilities
DelveInsight’s ‘Biliary Atresia (BA) Epidemiology Forecast 2030’ report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States